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Abstract
A-to-I RNA editing is a post-transcriptional modification of single nucleotides in RNA by adenosine deamination, which
thereby diversifies the gene products encoded in the genome. Thousands of potential RNA editing sites have been
identified by recent studies (e.g. see Li et al, Science 2009); however, only a handful of these sites have been independently
confirmed. Here, we systematically and quantitatively examined 109 putative coding region A-to-I RNA editing sites in three
sets of normal human brain samples by ultra-high-throughput sequencing (uHTS). Forty of 109 putative sites, including 25
previously confirmed sites, were validated as truly edited in our brain samples, suggesting an overestimation of A-to-I RNA
editing in these putative sites by Li et al (2009). To evaluate RNA editing in human disease, we analyzed 29 of the confirmed
sites in subjects with major depressive disorder and schizophrenia using uHTS. In striking contrast to many prior studies, we
did not find significant alterations in the frequency of RNA editing at any of the editing sites in samples from these patients,
including within the 5HT2C serotonin receptor (HTR2C). Our results indicate that uHTS is a fast, quantitative and high-
throughput method to assess RNA editing in human physiology and disease and that many prior studies of RNA editing
may overestimate both the extent and disease-related variability of RNA editing at the sites we examined in the human
brain.
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Introduction
Adenosine-to-inosine (A-to-I) RNA editing is a post-transcrip-
tional modification of RNA transcripts catalyzed by ADARs
(Adenosine Deaminases Acting on RNA). A-to-I RNA editing
converts genomically encoded adenosine to inosine, which is
recognized as guanosine by the translational apparatus [1,2]. Until
recently, only two dozen edited human genes were documented,
with the majority involved in central nervous system functions
[3,4,5,6,7,8]. The high proportion of brain-derived edited mRNAs
is not surprising given the high levels of expression of ADARs in
the brain [9,10]. RNA editing has been shown to be important
during the development of the brain [11] and ADAR1 knockout
mice are embryonically lethal [12] while ADAR2 knockout mice
display progressively severe epilepsy and, ultimately, death [13]. In
flies, inactivation of A-to-I RNA editing activity (e.g., in dADAR
mutant flies) also yields a neurological phenotype with locomotor
deficits, seizures and neurodegeneration [14].
In the mammalian brain, RNA editing finely tunes the functions
of many proteins involved in electrical and chemical neurotrans-
mission [3,7,13,15,16]. The RNA editing of subunit 2 of alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
glutamate receptor (GluR2), by changing the amino acid from
glutamine (Q) to arginine (R), leads to Ca2+ impermeability of
AMPA receptor containing GluR2 subunit [17]. The unedited
form of GluR2 mRNA is expressed in the various regions of the
developing brain, however nearly 100% edited form of GluR2
mRNA is expressed in the adult brain [17]. The disturbance of
RNA editing of GluR2 by the inactivation of ADAR2 results in the
progressively epilepsy and the death of mice in a few weeks [13].
The serotonin receptor HTR2C is the only G protein coupled
receptor shown to undergo RNA editing, with five editing sites (A,
B, E, C, D) within close proximity in the second intracellular loop
of the receptor. RNA editing of HTR2C receptor decreases the
efficacy of the interaction between the HTR2C and its G proteins,
and thus modulates serotonin signaling [3]. Dysregulated editing
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of HTR2C results in the constitutive activation of the sympathetic
nervous system and increased energy expenditure [18] and
a Prader-Willi-like syndrome [19]. In the human potassium
voltage-gated channel KCNA1, RNA editing recodes a highly
conserved isoleucine to a valine, thereby allowing the edited
channels to recover from inactivation about 20 times faster than
their unedited counterparts. This change in function of KCNA1
greatly influences the action potential shape, signal propagation
and the firing pattern [20]. The alpha3 subunit of GABAA
receptors has also been shown to undergo RNA editing, with an
isoleucine to a methionine change in the third transmembrane
region [7]. Such editing substantially alters GABA sensitivity and
the deactivation rate of GABA-A receptors, with the unedited
form showing a lower GABA EC50 and slower decay [21].
In contrast to these small scale studies, recent years have seen an
increasing number of potential A-to-I RNA editing sites identified
in the human transcriptome by genome wide analysis
[4,22,23,24,25,26,27,28,29,30]. Based on the A-to-G discrepan-
cies between genomic and cDNA sequences from human gene
database, Athanasiadis et al [22] and Levanon et al [23] found
14,500 and 12,723 editing sites in the human transcriptome,
respectively. To directly identify inosines on RNA strands, Sakurai
et al [26] developed a chemical method (Inosine chemical erasing,
ICE) and found 5,072 editing sites, including 4,395 new sites in
human transcriptome. Using a massively parallel target capture
and DNA sequencing approach, Li et al [24] detected several
hundred l RNA editing sites by comparing genomic DNA with
RNA from seven tissues of one individual. However, of the
thousands of potential A-to-I RNA editing sites identified by
previous studies, only a handful have been independently
validated–typically via non-quantitative and low-throughput
Sanger sequencing methods [4,11,23,24,26]. To accurately and
quantitatively verify the frequency of editing at these potential
RNA editing sites, we recently developed an ultra-high-throughput
sequencing approach [31] suitable for quantitatively analyzing
hundreds of potential RNA editing sites simultaneously in normal
and diseased tissues. Here, we used this uHTS approach to
examine 109 RNA editing sites in coding regions of human brain
transcriptome and analyzed 29 confirmed sites in psychiatric
disorders. We found that the extent of RNA editing from the sites
we examined in Li’s study [24] may be overestimated in normal
human brain, and the scale of RNA editing alterations may also be
overstated in psychiatric disorders.
Results and Disscussion
Validation of 109 Putative A-to-I RNA Editing Sites from
Previous Study in Human Brain
A-to-I RNA editing primarily occurs in the non-coding regions
of RNA, typically in Alu repeats, where it may indirectly affect
gene function by altering the spatiotemporal profiles of gene
expression [23]. RNA editing events that ‘‘re-code’’ pre-mRNAs
in the coding region are particularly important as they can directly
alter the biophysical and physiological properties of the resultant
gene products [3,6]. To evaluate the true prevalence of these A-to-
I RNA editing sites, we selected 109 putative editing sites,
including 25 previously confirmed editing sites from a recently
published database [24]. These 109 sites were purported to recode
pre-mRNAs in one or more brain samples, and the frequencies of
RNA editing ranged from 2% to 100% [24]. For our studies, three
independent sets of normal human brain samples were used to
quantify RNA editing: the first represents sample derived from the
cerebral cortex and cerebellum pooled from 10 normal humans
(Clontech); the second comprises one subject with 5 different brain
regions sampled (Stanley Medical Research Institute; SMRI); and
the third is of 5 normal humans with two brain regions sampled
(Human Brain Collection Core, Center for Psychiatric Neurosci-
ence (CPN), University of Mississippi Medical Center). As
previously detailed [31], we combined multiple samples in the
same sequencing lanes via barcoding to permit identification of
individual samples (for details, see the materials and methods).
DNA fragments containing the possible editing sites were
amplified by reverse transcription–polymerase chain reaction
(RT-PCR), and each amplicon was subjected to uHTS using an
Illumina Genome Analyzer II platform (see Fig. 1A for the
complete processing and analysis scheme). All of 109 amplicons
mapped uniquely to the human genome, and none of them
overlapped with pseudogenes which might confound the study as
shown in previous reports [27,32].
A total of 115 million reads were obtained from the three sets of
human brain samples. Reads containing ‘‘Ns’’, or short reads with
matching sequence shorter than 30 bp, were filtered out. After two
rounds of stringent filtering, 96.2 million reads were subsequently
mapped to the target sequences. The average coverage for each
site and each sample was 57,7976714 reads, and 95.2% editing
sites from three sets of brain samples had greater than a 10,000
read coverage (Fig. 1B; for details of coverage for each site see
Tables S1, S2, S3, S4). The A-to-G error rate for each editing site,
which could be introduced either during PCR amplification or
sequencing, was measured by quantifying the frequency of A-to-G
misreads in unedited sites, and was estimated to be
0.08%60.005%. Accordingly, an RNA editing frequency equal
to or less than 0.08% is considered to be ‘‘background’’ in our
system. A summary of the Illumina sequencing data is listed in
Table 1.
Based on the consistency between the samples and the
background A-to-G error rate in the system, three categories of
editing sites were identified. Category I consists of sites with an
editing frequency greater than 1%, which included 11 of the ‘new’
sites identified by Li et al [24] and 25 previously documented
RNA editing sites (Fig. 1C, Table 2 and S1). Category II contains
sites with an editing frequency between 0.08% and 1%, and
included four sites identified by Li et al [24]: AEBP1, KCNQ5
KIF1A and PTPRN2 (Table S2). Category III is comprised of sites
with an average editing frequency below our observed background
error rate of 0.08%, which included 65 sites identified by Li et al
[24] and is considered to be comprised of non-edited false positives
(Table S3). Four sites (ATXN7, BIN1, C1ORF175 and RSU1),
which we found to be single nucleotide polymorphisms (SNPs)
rather than editing events, was excluded from the three categories
(Table S4). To rule out the possibility of rare SNPs and mutations
in the genome at the editing sites, which may confound bona fide
RNA editing, we used PCR to amplify 15 sites from the matched
mRNA and genomic DNA samples from the same individuals,
and sequenced them by Sanger sequencing. In the matched
samples from three individuals we examined, an unambiguous
trace of guanosine was present at the editing sites with the editing
frequency above 10% quantitated by our approach in RNA
samples, whereas the genomic DNA showed only the presence of
adenosine (Fig. S3).
Previous studies have shown differences in the frequency of
RNA editing in different brain regions [33,34,35]. Accordingly, in
the first and second sets of normal human brain samples, we re-
analyzed the frequency of RNA editing of 36 sites from category I
in the cerebral cortex and cerebellum. Due to the low sample
number (n = 2), no statistics were done for this comparison;
however, a general trend for decreased RNA editing was found in
the cerebellum compared to the cortex. Notably, the frequencies
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of RNA editing at 7 sites, CCNI (R/G), CCNI (K/R), FLNB,
5HT2C (site B), 5HT2C (site C), 5HT2C (site E), and TRO, were
more than two fold different between the cerebellum and the
cortex (Fig. 2A and Table S1). In contrast, there was no significant
difference in the frequency of RNA editing at 36 sites from
category I between the anterior temporal cortex (ATC) and the
right frontal cortex (RFC) from the third set of normal human
samples (n = 5) (Fig. 2B). The difference in RNA editing between
the cortex and cerebellum suggest that A-to-I RNA editing may
play an important physiological role in different brain regions.
However, due to the low sample number (n = 2) in present study,
Figure 1. Ultra-high-throughput sequencing of potential A-to-I RNA editing sites. A. Shows a schematic diagram of processing and
measuring RNA editing using ultra High Throughput Sequencing technology. B. Shows the frequency distribution of sequencing coverage for each
editing site. The reads for each editing site from three sets of normal human brain samples were grouped in intervals of 5,000 reads. Using the
D’Agostino-Pearson normality test, the data do not differ significantly from a Gaussian distribution. C. Shows the A-to-I RNA editing frequency of 36
sites from category I, including 11 ‘new’ sites and 25 known sites in three sets of normal human samples. RNA editing frequency is presented as
mean, expressed as a percentage of the total population of transcripts, 6 SEM.
doi:10.1371/journal.pone.0043227.g001
RNA Editing and Ultra-High-Throughput Sequencing
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e43227
a larger number of samples will be needed to be examined to
definitively address this issue.
Of 109 putative RNA editing sites [24], we were able to
confirm 40 sites (36.7%), 36 sites from category I and 4 sites
from category II, to be truly edited in the human brain samples
we evaluated. These sites have been shown in the previous
study to be edited in one or more brain samples, with
frequencies of RNA editing ranged from 2% to 100% [24].
Several factors likely contribute to the high apparent false
positive rate (63.3%) of A-to-I RNA editing in prior study.
Firstly, in the prior report, the sequencing coverage for each site
was quite low (36.1% sites had less than 10 reads, 73.2% sites
had less than 100 reads and 95.2% sites had less than 1,000
reads in all tissue samples); indeed, some sites with as few as
10 total reads per tissue were considered to have adequate
sequence coverage in their study [24]. In our study, by contrast,
the coverage for each site was much higher than prior study,
95.2% RNA editing sites had more than 16104 reads and only
1.9% sites had less than 1,000 reads in three sets of brain
samples. One general problem of all current next generation
sequencing (NGS) reads is their higher error rate compared
with Sanger sequencing [36]. It has been well described in the
literature that the accuracy is dramatically diminished by low
coverage in the NGS platform [37]. To accurately measure the
frequency of RNA editing, which may range from 0% to 100%,
a much higher coverage is required to compensate for
sequencing error. Secondly, the relative fidelity of DNA
amplification with Taq DNA polymerase (e.g., as used by Li
et al. [24]) is low, and this will potentially significantly affect the
results, as incorrect nucleotides can be incorporated during the
initial amplification steps. In our study, the highest fidelity DNA
polymerase available was used in the initial cDNA amplification,
and its fidelity is at least 50-fold higher than that of Taq DNA
polymerase (http://www.neb.com/nebecomm/products/
productM0530.asp). Thirdly, some SNPs (single nucleotide
polymorphisms) appear to be mis-annotated as RNA editing
sites, e.g., ATXN7 (GenBank ID: rs1053338), Bin1 (GenBank
ID: rs138047593) (Table S4), C1ORF175 (GenBank ID:
rs75269200) and RSU1 (GenBank ID: rs11539866). The A-to-
G rate of ATXN7 is 13.21% in the cerebellum and 5.11% in
the cortex from the pooled samples, and is ,50% in two brain
regions from same subject. The A-to-G rate of BIN1 is 7.58%
in the pooled cerebellum sample and is around ‘‘background’’
level in other samples (Table S4). Thus, the highly inconsistent
rates of A-to-G substitution between samples suggest that single
nucleotide polymorphisms rather than RNA editing may be
responsible. Based on our results, it appears that the A-to-I
RNA editing frequencies of 109 putative sites reported in the
previous study [24] may be overestimated in human brain.
However, we can’t exclude the possibility that the discrepancy
may be due to different samples used in our study and previous
study.
A-to-I RNA Editing in Schizophrenia, Major Depressive
Disorder and Suicide
Previous studies have shown that the frequencies of RNA
editing in GluR2 [38,39], GRIK2 [40] and 5HT2C receptor
[41,42,43,44,45,46] were altered in human psychiatric disorders.
Alterations in RNA editing of the 5HT2C receptor have been
implicated in schizophrenia, major depressive disorder and in
suicide. However, the results have been highly inconsistent among
studies and, given the methodology used, inconclusive
[41,42,43,44,47,48] (for recent review see [49]). To address the
potential significance of RNA editing in human psychiatric
disorders, 29 editing sites from 19 genes (including the 5HT2C
receptor) were selected from Category I (vide supra) and examined
in five groups of a total of 72 subjects: age-, sex-, tissue pH- and
post-mortem interval (PMI)-matched controls (n = 15), major
depressive disorder (MDD, n= 15), MDD with suicide (n = 15),
schizophrenia (n = 15) and schizophrenia(7)/schizoaffective disor-
der(5) with suicide (n = 12). The right prefrontal cortex (Brodmann
Areas 8/9) was sampled. There were no significant differences in
age, gender, PMI and tissue pH among the groups (Table S5).
A total of 141 million reads were obtained from the 72 human
samples, and of these, 91.5 million reads were mapped to the
target sequences. The coverage for each site and each sample
averaged 53,4586939 reads and the average A-to-G error rate
was calculated to be 0.07% 60.004% (Table 1). The editing
frequency for each site from this cohort of 72 brain samples is thus
consistent with the aforementioned three sets of normal brain
samples. A general trend for decreased RNA editing was found in
the MDD and schizophrenia groups compared to the control
group, while no significant difference were identified at any sites
(Fig. S1 and Table S6).
Although several previous studies [41,42,43,46,47] have re-
ported alterations of editing of 5HT2C serotonin receptor mRNA
in both schizophrenia and MDD, our results demonstrated no
significant differences between these groups in the brain samples
we studied, although a slight decrease of editing at sites C, D and E
occurred in the MDD and schizophrenia groups compared to
controls (Table S6 and S7). When we separately analyzed the 24
protein isoforms of the 5HT2C receptor produced by RNA editing,
no significant difference were also identified between these groups
at any isoforms of 5HT2C serotonin receptor (Fig. S2 and Table
S8).
RNA integrity is a major concern in studies using postmortem
brain tissues and this may be affected by agonal factors, such as the
specific agonal conditions at the time of death and agonal duration
[50]. The pH of postmortem brain tissue has been reported to be
inversely related to the agonal state at the time of death [51]. In
Table 1. Summary of Illumina sequencing data.
Samples Total reads Mapped reads Coveragea A-to-G error rateb
2 normal human brain samples (Pooled, Clontech) 18,086,205 16,235,725 84,78762,059 0.083%60.011%
5 (SMRI) and 10 (CPN) normal human brain samples 96,677,697 79,992,527 54,3006710 0.074%60.006%
72 psychiatric disorders and control human brain
samples (CPN)
141,226,208 91,482,049 53,4586939 0.070%60.004%
aCoverage is the number of reads covered in each site, presented with Mean 6 SEM.
bA-to-G error rate was measured by quantifying the frequency of A-to-G misreads in unedited sites, presented with Mean 6 SEM.
doi:10.1371/journal.pone.0043227.t001
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our study, there is a slight, but insignificant, lower pH value in
MDD and schizophrenia groups compared to other groups, which
coincides with a trend for decreased RNA editing in these two
groups. Harrison et al [51] have found that prolonged agonal
states may produce brain pH values ,6.0 and have recommended
the exclusion of samples with a pH value ,6.1. Thus, here we
used a pH of 6.1 as cutoff to separate the subjects into two
subgroups, low pH (,6.1) and normal pH ($6.1). We found that 8
of 72 brain samples, distributed among all five subject groups, had
low pH values. Those samples were then sub-grouped post-hoc, and
eight matched samples with normal pH were selected as controls.
A dramatic decrease of RNA editing was found in the low pH
subgroup (e.g., CYFIP (K/E) p,0.01, GRIA2 (R/G) p,0.05,
GRIA3 p,0.05, GRIK2 (Y/C) p,0.01, GRIK2 (Q/R) p,0.05,
KCNMA1 p,0.05) compared to the normal pH subgroup, and
there was a statistically significant difference between the two
subgroups (paired t-test, p,0.001) (Fig. 3C and Table S10).
Therefore, the frequency of RNA editing observed in post-mortem
samples appears to be inversely related to the tissue pH and agonal
state. Prolonged low brain pH in the agonal state could
conceivably inactivate ADARs and decrease the efficiency of
RNA editing. The alterations of RNA editing of the 5HT2C
Table 2. A-to-I RNA editing sites with the frequency of editing above 1% in three sets of normal human samples.
Gene Name Site Genomic positiona Frequency of RNA editingb (Mean6SEM) Readsc (Mean6SEM)
AZIN1d S/G chr8:103910812 6.9660.88 71,19266,463
BLCAP Y/C chr20:35580986 36.8461.76 13,04062,405
BLCAP Q/K chr20:35580977 37.2262.43 13,04062,406
BLCAP K/R chr20:35580947 12.9660.68 13,04062,407
CCNId R/G chr4:78198704 19.7361.71 92,64766,897
CCNId K/R chr4:78196188 4.2560.40 99,32765,241
CRB2d T/A chr9:125172441 2.6360.24 36,33663,848
CYFIP2 K/E chr5:156669386 69.8364.38 72,19264,190
CYFIP2d K/R chr5:156669387 1.2460.08 72,19264,191
FLNA Q/R chrX:153233144 18.8362.09 59,72564,313
FLNBd Q/R chr3:58116841 5.4861.44 58,46164,517
GABRA3 I/M chrX:151108975 74.0863.20 65,17565,507
GLI1d R/G chr12:56150891 64.8963.14 51,89764,292
GRIA2 Q/Q chr4:158477325 99.0960.43 81,66864,010
GRIA2 Q/R chr4:158477329 17.8360.98 81,66864,011
GRIA2 R/G chr4:158500744 58.9164.75 24,30862,737
GRIA3 R/G chrX:122426643 91.5963.00 35,14361,593
GRIA4 R/G chr11:105309904 3.6560.38 13,65162,085
GRIK1 Q/R chr21:29875621 56.9262.67 72,06563,592
GRIK2 I/V chr6:102444382 55.7862.92 52,96063,377
GRIK2 Y/C chr6:102444395 81.7963.52 52,96063,378
GRIK2 Q/R chr6:102479281 77.2662.89 42,99463,236
5HT2C A (I/V) chrX:113988938 68.0264.11 63,90164,434
5HT2C B(I/M) chrX:113988940 41.7864.15 63,90164,435
5HT2C E(N/D) chrX:113988944 15.1261.60 63,90164,436
5HT2C C(N/S) chrX:113988945 45.8763.16 63,90164,437
5HT2C D(I/V) chrX:113988950 56.2162.63 63,90164,437
IGFBP7 R/G chr4:57671043 14.9062.52 1,2366919
IGFBP7 K/R chr4:57670991 49.7661.93 29,16763,948
KCNA1 I/V chr12:4892003 14.5961.38 62,44763,825
KCNMA1d S/G chr10:79067304 20.6661.57 43,53463,777
NCSTNd S/G chr1:158586611 9.0860.90 75,68966,413
NEIL1 K/R chr15:73433139 98.8060.25 7,65161,655
NEIL1 K/K chr15:73433140 92.1260.88 7,65161,656
TROd S/G chrX:54972292 9.5560.95 52,31267,660
TTLL3d K/R chr3:9851560 4.1760.39 54,05764,098
aGenomic position is the position in human genomic database from UCSC (http://genome.ucsc.edu, hg18 version, March 2006 assembly).
bFrequency of RNA editing is presented as the percentage of the total population of transcripts.
cReads is the number of transcripts sequenced.
d11 new RNA editing sites identified by Li et al [24].
doi:10.1371/journal.pone.0043227.t002
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Figure 2. A-to-I RNA editing is different between the cortex and cerebellum, but not different between two regions of cortex, in
human brain. A. Shows the distribution of A-to-I RNA editing frequency of 36 sites from category I, including 11 of the ‘new’ sites identified by Li
et al (ref 24) and 25 previously ‘known’ sites, in the cortex and cerebellum from two sets of normal human brain samples. The RNA editing frequency
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receptor observed in previous studies [41,42,43,46,47], thus may
be due to differences in the agonal state of the subjects. As tissue
pH affects the efficiency of RNA editing, 8 subjects with low pH
(,6.1) were excluded from our study in a separate post-hoc analysis
(Table S7). After reanalyzing the data, the conclusions regarding
RNA editing of the 29 sites were not significantly changed,
presumably due to the even distribution of low pH samples
through all five groups. No significant differences were identified
between these groups at all RNA editing sites we evaluated (Fig. 3A
and Table S7) and any isoforms of 5HT2C serotonin receptor in
the brain samples we studied upon re-analysis of the data. (Fig. 3B
and Table S9).
In summary, we have systematically and quantitatively exam-
ined 109 putative coding region A-to-I RNA editing sites by ultra-
high-throughput sequencing (uHTS) in human brain. Only 40 of
109 sites identified by Li’s (ref 24) study were confirmed in our
brain samples, which may suggest an overestimation of these RNA
editing sites in the human brain. After analyzing the prefrontal
cortex samples from MDD and schizophrenia in our study, we did
not find any significant alterations in the frequency of RNA editing
at any RNA editing sites we evaluated, including the sites of the
5HT2C receptor transcripts, also in contrast with many previous
studies. Our findings, however, do indicate that uHTS is a fast,
powerful and quantitative method for assessing RNA editing in
human tissues provided adequate attention is paid to experimental
variables including tissue pH, estimations of sequencing and
amplification errors, and statistical power considerations. uHTS of
known RNA editing sites on multiple samples, as done in the
present study, provides a more robust testing of focused hypotheses
than more-or-less random whole-genome sequencing of one or
even a few samples, with its attendant low coverage at each site.
The results neither support many previous findings that large-scale
alterations in RNA editing occur in psychiatric disorders nor the
recent proposals that large numbers of genes contain coding
regions is RNA edited.
Materials and Methods
Human RNA and Tissue Samples and Psychiatric
Assessment
Human cortex and cerebellum total RNA from pooled normal
human control samples (n = 10) were obtained from Clontech.
Tissue samples from a normal control subject containing 5 different
brain areas (premotor cortex (Brodmann areas 6), motor cortex
(Brodmann area 4), parietal cortex (Brodmann area 7), occipital
cortex (Brodmann area 19), and cerebellum) were obtained from the
Stanley Medical Research Institute (SMRI, Chevy Chase, Mary-
land). The age, PMI, and average tissue pH of this subject was
37 years, 50 hours, and pH 6.61. Tissue samples from a normal
control cohort containing 5 subjects, two brain regions (right
anterior temporal cortex and right prefrontal cortex (Brodmann
areas 38 and 8/9, respectively)) were obtained from the Human
Brain Collection Core (Center for Psychiatric Neuroscience,
University of Mississippi Medical Center, Jackson, Mississippi).
The average age, PMI, and tissue pH of the cohort was
48.4612.15 years, 20.4966.63 hours, and pH 6.5760.3. Samples
from a 72 patient cohort (one brain region - right prefrontal cortex
(Brodmann areas 8/9)) was obtained from the Human Brain
Collection Core and consisted of five groups: normal controls
(n = 15), major depressive disorder (MDD) (n = 15), major de-
pressive disorder who committed suicide (MDD suicide) (n = 15),
schizophrenia (SCZ) (n = 15), schizophrenia (7)/schizoaffective
disorder (5) who committed suicide (SCZ suicide) (n = 12). Detailed
information for this cohort is shown in Table S5.
All tissues from the Human Brain Collection Core were
collected at autopsy at the Cuyahoga County Coroner’s Office,
Cleveland, OH, using an ethical protocol approved by the
Institutional Review Board of the University Hospitals of Cleve-
land and the University of Mississippi Medical Center. Informed
written consent was obtained from the next-of-kin for all subjects.
Informed consent for tissue donation at autopsy and a subsequent
psychiatric assessment was sought from the legally-defined, adult
next-of-kin of the deceased. The next-of-kin of the deceased were
contacted by telephone, informed of the broad goals of the study
and asked to participate by permitting sampling of tissue as well as
agreeing to an interview held about three months later. If the
family declines to participate, they are not re-contacted and no
tissue is collected. If the family indicates a willingness to
participate, written consent is obtained shortly thereafter by
a research coordinator, after which the coroner releases the tissues
for dissection, freezing and storage. Included with the informed
consent form is a request to obtain medical records of the
deceased. An appropriate, IRB-approved HIPAA Authorization
Form is used in requesting relevant personal health information
from doctors and/or hospitals identified by the next-of-kin or
coroner’s records. If written consent is not received, no tissue is
sampled nor are the families contacted again. All potential
participants who do not consent to the study are not disadvantaged
in any way by not participating in the study. After an initial
contact, those who decline to participate are not contacted again.
Cortical tissues were frozen in isopentane cooled by dry ice and
stored at 280uC. The causes of death – natural, accidental or
suicide – were determined by the coroner. Toxicology screening of
postmortem blood and urine was performed by the coroner’s
office. An antidepressant medication was present in four subjects
with MDD and five subjects with schizophrenia. An antipsychotic
medication was present in four subjects with schizophrenia. A
trained interviewer assessed Axis I psychopathology for each
subject by a structured clinical interview with knowledgeable next-
of-kin, as previously described [52]. Consensus diagnosis was
reached during meeting when all available information was
reviewed by a psychiatrist, clinical psychologist, and social worker,
and discussed until a consensus was reached. None of the control
subjects had ever met criteria for an Axis I major mental illness.
All 30 depressed subjects met diagnostic criteria for major
depressive disorder (MDD) according to the Diagnostic and
Statistical Manual of Mental Disorders IV (DSM-IV,4th ed, 1994).
All depressed subjects met criteria for a major depressive episode
within the last two weeks of life except for three non-suicides: two
depressed subjects were in partial remission and one was in full
remission. Twenty two and five subjects met DSM-IV criteria for
schizophrenia and schizoaffective disorder, respectively. Among
depressed subjects committing suicide, the following comorbid
diagnoses were noted: alcohol dependence (2), alcohol abuse (2),
is presented as a percentage of the total population of transcripts. A two-fold increase of RNA editing frequency at 6 sites (CCNI (R/G), CCNI (K/R),
5HT2C (siteB), 5HT2C (siteC), 5HT2C (siteE) and TRO) in cortex and one site (FLNB) in cerebellum are shown in the inset. B. Shows the distribution of A-
to-I RNA editing frequency of 36 sites from category I, in the anterior temporal cortex (ATC) and the right frontal cortex (RFC) from the third set of
normal human samples (n = 5). The RNA editing frequency is presented as a percentage of the total population of transcripts. No significant
difference was found between these two regions of cortex.
doi:10.1371/journal.pone.0043227.g002
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alcohol and cannabis abuse (1). Among depressed subjects not
committing suicide, the following comorbid diagnoses were noted:
opiate dependence (1), cannabis dependence (1), alcohol de-
pendence and polysubstance abuse (1), polysubstance abuse (2).
Among subjects with a psychotic disorder committing suicide, the
following comorbid diagnoses were noted: cannabis dependence
(1), polysubstance abuse (1) and alcohol dependence and cannabis
abuse (1). Among subjects with a psychotic disorder not
committing suicide, the following comorbid diagnoses were noted:
alcohol dependence and cannabis abuse (2) alcohol dependence (1)
and cannabis abuse (1).
RNA Extraction and RT-PCR
Trizol (Invitrogen) was used to extract RNA from ,123 mg of
each human brain sample. Ten mg of RNA was treated with
DNAse (DNA-free, Ambion), and 2 mg of the DNase-treated RNA
was added to a reverse transcription reaction performed using the
SuperscriptTM III RNase H Reverse Transcriptase kit (Invitro-
gen) with random hexamer primers (Invitrogen). The cDNA
product was used as template to generate a double stranded DNA
fragment by PCR for use in high throughput sequencing
experiments.
One mL of cDNA (of 20 mL) was used as template for a 20 mL
PCR reaction (conditions: 1 cycle298uC, 1 min; 35 cycles298uC
10 sec, 68uC 15 sec, 72uC 15 sec; 1 cycle272uC 5 min) to amplify
a fragment containing the edited region of interest using Phusion
Hot Start High-Fidelity DNA Polymerase (New England BioLabs).
The error rate of Phusion DNA Polymerase is 4.461027 (http://
www.finnzymes.fi/pcr/phusion_products.html). PCR fragments
(106–233 base pairs in length) were diluted 6X, and 5 mL were
used as template for a second round of PCR (50 mL reaction) (the
conditions for this 2nd round were the same as for the 1st round).
PCR fragments were purified using the QIAquick96 PCR
Purification kit (Qiagen) and 5 ul of product was run on a 1.5%
agarose gel to determine quality and quantity of amplification. In
order to confirm amplification of the correct gene with the correct
tag, 5 ul of each PCR product was submitted for Sanger
sequencing. The primers used for amplification are listed in Table
S11. Each primer used for amplification contained adapter
sequences necessary for cluster generation. In addition, the forward
primer contained a sequence corresponding to a sequence primer
optimized by Illumina for use in the Genome Analyzer II
(uppercase letters not in bold), as well as a sample-identification
‘‘barcode’’. All ‘‘barcodes’’ used in the experiment were listed in
Table S12, which were designed with 3 A/Ts and 3 G/Cs.
Ultra High Throughput Sequencing
For sequencing of the Clontech samples, two ‘‘barcodes’’ were
used (cortex and cerebellum); PCR products of 96 genes from two
samples were mixed in equal parts and designated for one lane in
the Genome Analyzer II flow cell. Five ‘‘barcodes’’ were used for
the five-patient, two-brain area normal control cohort samples
from the Human Brain Collection Core, as well as the one-patient,
five brain-area normal control samples from the Stanley Medical
Research Institute (SMRI) to differentiate a similar number of
genes and editing sites as above for each tissue sample. PCR
products from five samples were then mixed in equal parts
creating three mixed sample sets, each set designated for one lane
in the Genome Analyzer II flow cell. For the cohort of the 72
human psychiatric and control samples, 12 different ‘‘barcodes’’
were used to differentiate 19 genes and 29 edited sites for each
sample, which were then mixed in equal parts to create 6 sample
sets, each set designated for one lane in the Genome Analyzer II
flow cell. The process of Ultra high throughput sequencing was
similar to our previous publication. Briefly, purified PCR products
were diluted to a concentration of 15 nM. 2 mL of the diluted
PCR product was used for denaturation (total volume 20 mL).
4 mL of the denaturation mixture was diluted in 996 mL of
hybridization solution. The hybridization mixture (final DNA
concentration about 6 pM) was loaded into the Cluster Station for
cluster generation. Primer hybridization was performed on the
Cluster Station using 6.6 mL of 500 nM sequencing primer
(Primer sequence: 59-acactctttccctacacgacgctcttccgatct-39) diluted
in 1313 mL of hybridization buffer. Cluster generation was
performed for 76 cycles followed by base-by-base sequencing
initiated by the sequencing primer on the Genome Analyzer II.
The Genome Analyzer II uses two different lasers to excite the dye
attached to each nucleotide. Since the emission spectra of these
four dyes overlap, the four images thus obtained are not
independent. As in Sanger sequencing, the frequency cross-talk
is deconvolved using a frequency cross-talk matrix. Therefore, the
crosstalk matrix calculation requires control lanes for samples with
skewed base compositions. Thus, a control human genomic DNA
sample was run in parallel on the same flowcell concurrently with
the human RNA editing samples.
Data Analysis and Statistics
Sequences were analyzed using a Perl 5 script (available for
download at http://pdsp-temp.pha-med.unc.edu/Download/
code.php) written by us to filter the data through two rounds of
filters and sort the data that passed through the filters. Reads
containing ‘‘Ns’’, or short reads mapped to the target region
shorter than 30 bp, were filtered out. The mapped reads equal or
large than 30 bp were counted. The percentage of RNA editing
was calculated by the number of reads containing ‘‘G’’ at the
editing site divided by the total number of reads containing ‘‘A’’ or
‘‘G’’ at the editing site. The human genomic reference sequence
for analysis was downloaded from UCSC (http://genome.ucsc.
edu, hg18 version, March 2006 assembly). The A-to-G error rate
for each editing site investigated was determined by measuring the
rate of A-to-G misreads within a few base pairs of each editing site.
Further data analysis was performed in Microsoft Excel and
Figure 3. A-to-I RNA editing in brain is not altered in various psychiatric disorders. A. Shows A-to-I RNA editing frequency of 29 sites from
category I in psychiatric patients and normal controls, excluding 8 samples with pH ,6.1. RNA editing frequency is presented as mean, expressed as
a percentage of the total population of transcripts, 6 SEM. The data were analyzed by t-test with Benjamini–Hochberg correction for multiple
comparisons using a P value of 0.05 as the criterion for statistical significance. The editing frequency in patients did not differ significantly from
controls for any site tested. B. Shows the expression patterns of 24 isoforms of the 5HT2C receptor produced by RNA editing in psychiatric patients
and normal controls, excluding 8 samples with pH,6.1. The RNA editing frequency is presented as mean, expressed as a percentage of the total
population of transcripts,6 SEM. The data were analyzed by s t-test with Benjamini–Hochberg correction for multiple comparisons using a P value of
0.05 as criterion of statistical significance. Editing frequency in patients did not differ significantly from controls for any site tested. C. Shows the
frequency of A-to-I RNA editing of 29 sites from category I was examined in 8 samples with pH,6.1 and 8 matched samples with pH $6.1. The RNA
editing frequency is presented as mean, expressed as a percentage of the total population of transcripts, 6 SEM. The data were analyzed by t-test
with Benjamini–Hochberg correction. Significant differences between the normal pH group and low pH group are shown by asterisks (*p,0.05;
**p,0.01), and were seen in 6 of 29 sites examined.
doi:10.1371/journal.pone.0043227.g003
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Graphpad Prism 5.0. All statistical analyses were performed in
Graphpad Prism 5.0. For purposes of making statistical compar-
isons in the cohort of 72 human psychiatric and control samples,
all reads generated from one sample were treated as one
experiment (N=12215 for each sub cohort). The data were
analyzed by two-tailed t-test and subsequent Benjamini–Hochberg
correction for multiple comparisons using a P value of 0.05 as
criterion of statistical significance.
Supporting Information
Figure S1 A-to-I RNA editing frequency of 29 sites from
category I in psychiatric patients and normal controls,
including 8 samples with pH,6.1. RNA editing frequency is
presented as mean, expressed as a percentage of the total
population of transcripts, 6 SEM. The data were analyzed by t-
test with Benjamini–Hochberg correction for multiple compar-
isons using a P value of 0.05 as criterion of statistical significance.
(TIF)
Figure S2 Expression pattern of 24 isoforms of the
5HT2C receptor produced by RNA editing in psychiatric
patients and normal controls, including 8 samples with
pH,6.1. The RNA editing frequency is presented as mean,
expressed as a percentage of the total population of transcripts, 6
SEM. The data were analyzed by t-test with Benjamini–Hochberg
correction for multiple comparisons using a P value of 0.05 as
criterion of statistical significance.
(TIF)
Figure S3 Validation of RNA editing sites by Sanger
sequencing. 15 RNA editing sites were verified by Sanger
sequencing with the matched genomic DNA and cDNA samples
from the same individuals. RNA editing was indicated by a trace
of guanosine in cDNA sequence, while the genomic DNA
sequence shown only adenosine signals. The RNA editing sites
with the frequency above 10% measured by our approach have
shown a clear signal of guanosine.
(TIF)
Table S1 Category I RNA editing sites with .1% A-to-I
RNA editing in three sets of normal human samples.
RNA editing frequency is presented as the percentage of the total
population of transcripts. Three independent sets of normal
human samples were used in this study. The first is the cortex and
cerebellum pooled from 10 normal humans; the second comprises
one subject (ID: S343) with 5 different brain regions sampled
(Stanley Medical Research Institute; SMRI) and the third is of 5
normal humans (ID:228-451, 228-612, 228-695, 229116, 244-079)
and two brain regions, anterior temporal cortex (ATC) and right
frontal cortex (RFC, Brodmann areas 8&9) (Human Brain
Collection Core). 11 new RNA editing sites are shown in red.
The values of RNA editing frequency in the cerebellum, which
were more than 1.5 fold different from the cortex, were
highlighted.
(XLSX)
Table S2 Category II RNA editing sites with 0.08%–1%
A-to-I RNA editing in three sets of normal human
samples. RNA editing frequency is presented as the percentage
of the total population of transcripts. Three independent sets of
normal human samples were used in this study. The firstt is the
cortex and cerebellum pooled from 10 normal humans; the second
comprises one subject (ID: S343) with 5 different brain regions
sampled (Stanley Medical Research Institute; SMRI) and the third
is of 5 normal humans (ID:228-451, 228-612, 228-695, 229116,
244-079) and two brain regions, anterior temporal cortex (ATC)
and right frontal cortex (RFC, Brodmann areas 8&9) (Human
Brain Collection Core). The values of RNA eidting frequency
above 0.08% were highlighted.
(XLSX)
Table S3 RNA editing frequency (%) in category III
sites with ,0.08% A-to-I RNA editing in three sets of
normal human samples. RNA editing frequency is presented
as the percentage of the total population of transcripts. Three
independent sets of normal human samples were used in this
study. The first is the cortex and cerebellum pooled from 10
normal humans; the second comprises one subject (ID: S343) with
5 different brain regions sampled (Stanley Medical Research
Institute; SMRI) and the third is of 5 normal humans (ID:228-451,
228-612, 228-695, 229116, 244-079) and two brain regions,
anterior temporal cortex (ATC) and right frontal cortex (RFC,
Brodmann areas 8&9) (Human Brain Collection Core).
(XLSX)
Table S4 Four single nucleotide polymorphisms (SNP)
were misannotated as RNA editing in three cohorts of
normal human samples. RNA editing frequency is presented
as the percentage of the total population of transcripts. Three
independent sets of normal human samples were used in this
study. The first is the cortex and cerebellum pooled from 10
normal humans; the second comprises one subject (ID: S343) with
5 different brain regions sampled (Stanley Medical Research
Institute; SMRI) and the third is of 5 normal humans (ID:228-451,
228-612, 228-695, 229116, 244-079) and two brain regions,
anterior temporal cortex (ATC) and right frontal cortex (RFC,
Brodmann areas 8&9) (Human Brain Collection Core). The values
of A-to-G rate greater than 0.08% were highlighted.
(XLSX)
Table S5 Characterization of 72 human psychiatric and
control samples. The values are presented as mean 6 SEM.
PMI: post-mortem interval.
(XLSX)
Table S6 A-to-I RNA editing frequency (%) of 29 editing
sites from 19 genes in normal and psychiatric disease
patients. RNA editing frequency is presented as mean, expressed
as a percentage of the total population of transcripts, 6 SEM.
Data were analyzed by t-test with Benjamini–Hochberg correction
for multiple comparisons using a P value of 0.05 as criterion of
statistical significance.
(XLSX)
Table S7 A-to-I RNA editing frequency (%) of 29 editing
sites from 19 genes in normal and psychiatric diseases
patients excluding 8 low pH samples. RNA editing
frequency is presented as mean, expressed as a percentage of the
total population of transcripts, 6 SEM. The data were analyzed
by t-test with Benjamini–Hochberg correction for multiple
comparisons using a P value of 0.05 as criterion of statistical
significance.
(XLSX)
Table S8 Distribution of the frequency (%) of 24
isoforms of 5HT2C receptors produced by RNA editing
in normal and psychiatric disorder patients. 5-HT2C
receptor isoform frequency is presented as mean, expressed as
a percentage of the total population of transcripts, 6 SEM. The
data were analyzed t-test with Benjamini–Hochberg correction for
multiple comparisons using a P value of 0.05 as criterion of
statistical significance.
(XLSX)
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Table S9 Distribution of the frequency (%) of 24
isoforms of 5HT2C receptors produced by RNA editing
in normal and psychiatric disorder patients (excluding 8
low pH samples). 5-HT2C receptor isoform frequency is
presented as mean, expressed as a percentage of the total
population of transcripts, 6 SEM. The data were analyzed by t-
test with Benjamini–Hochberg correction for multiple compar-
isons using a P value of 0.05 as criterion of statistical significance.
(XLSX)
Table S10 A-to-I RNA editing frequency (%) of 29
editing sites from 19 genes in normal pH (pH .6.1)
and low pH (pH ,6.1) samples. RNA editing frequency is
presented as mean, expressed as a percentage of the total
population of transcripts, 6 SEM. Data were analyzed by t-test
with Benjamini–Hochberg correction for multiple comparisons
using a P value of 0.05 as criterion of statistical significance. The
significant differences between the control group and other groups
are shown by asterisks (*p,0.05; **p,0.01).
(XLSX)
Table S11 The primers used in the study. All primers are
in the 59-to-39 direction from left to right. One ‘‘barcode’’
(CAGCTA) was used to illustrate this set of primers. See Table
S11 for all ‘‘barcodes’’ used in the study.
(XLSX)
Table S12 The ‘‘barcodes’’ used in the study.
(XLSX)
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